Dominik Steubl1, Petra Buzkova2, Pranav S Garimella3, Joachim H Ix3, Prasad Devarajan4, Michael R Bennett4, Paolo H M Chaves5, Michael G Shlipak6, Nisha Bansal7, Mark J Sarnak8. 1. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA; Division of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 2. Department of Biostatistics, University of Washington, Seattle, WA. 3. Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA. 4. Department of Nephrology and Hypertension, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH. 5. Benjamin Leon Center for Geriatric Research and Education, Herbert Wertheim College of Medicine, Florida International University, Miami, FL. 6. Division of General Internal Medicine, University of California San Francisco, San Francisco, CA. 7. Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA. 8. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA. Electronic address: msarnak@tuftsmedicalcenter.org.
Abstract
RATIONALE & OBJECTIVE: Uromodulin is released by tubular epithelial cells into the serum and lower levels are associated with more severe interstitial fibrosis and tubular atrophy. Low serum uromodulin (sUMOD) levels are associated with mortality and cardiovascular disease. However, little is known about the association of sUMOD levels with long-term kidney outcomes in older adults, a population with a high prevalence of interstitial fibrosis and tubular atrophy. STUDY DESIGN: Case-cohort study and case-control study. SETTING & PARTICIPANTS: Random subcohort (n=933) and additional cases of end-stage kidney disease (ESKD) and kidney function decline (≥30% decline in estimated glomerular filtration rate [eGFR]) during follow-up of the Cardiovascular Health Study (CHS). PREDICTOR: sUMOD level. OUTCOMES: ESKD (n=14) from the random subcohort and all additional ESKD cases from outside the random subcohort (n=39) during follow-up (10 years, case-cohort study); kidney function decline of≥30% eGFR at 9 years of follow-up in individuals with repeated eGFR assessments from the random subcohort (n=56) and additional cases (n=123). 224 participants from the random subcohort served as controls (case-control study). ANALYTICAL APPROACH: Modified multivariable Cox regression for ESKD and multivariable logistic regression for kidney function decline. Both analyses adjusted for demographics, eGFR, urinary albumin-creatinine ratio, and other kidney disease progression risk factors. RESULTS: Mean age of the random subcohort was 78 years, 40% were men, 15% were black. Mean sUMOD level was 127±64ng/mL and eGFR was 63±19mL/min/1.73m2. In multivariable analysis, each 1-SD higher sUMOD level was associated with 63% lower risk for ESKD (HR, 0.37; 95% CI, 0.14-0.95). In demographic-adjusted analyses of kidney function decline, each 1-SD higher sUMOD level was associated with 25% lower odds of kidney function decline (OR, 0.75; 95% CI, 0.60-0.95); after multivariable adjustment, the association was attenuated and no longer significant (OR, 0.88; 95% CI, 0.68-1.14). LIMITATIONS: Possibility of survival bias in the kidney function decline analysis. CONCLUSIONS: Higher sUMOD levels may identify elderly persons at reduced risk for ESKD.
RATIONALE & OBJECTIVE:Uromodulin is released by tubular epithelial cells into the serum and lower levels are associated with more severe interstitial fibrosis and tubular atrophy. Low serum uromodulin (sUMOD) levels are associated with mortality and cardiovascular disease. However, little is known about the association of sUMOD levels with long-term kidney outcomes in older adults, a population with a high prevalence of interstitial fibrosis and tubular atrophy. STUDY DESIGN: Case-cohort study and case-control study. SETTING & PARTICIPANTS: Random subcohort (n=933) and additional cases of end-stage kidney disease (ESKD) and kidney function decline (≥30% decline in estimated glomerular filtration rate [eGFR]) during follow-up of the Cardiovascular Health Study (CHS). PREDICTOR: sUMOD level. OUTCOMES: ESKD (n=14) from the random subcohort and all additional ESKD cases from outside the random subcohort (n=39) during follow-up (10 years, case-cohort study); kidney function decline of≥30% eGFR at 9 years of follow-up in individuals with repeated eGFR assessments from the random subcohort (n=56) and additional cases (n=123). 224 participants from the random subcohort served as controls (case-control study). ANALYTICAL APPROACH: Modified multivariable Cox regression for ESKD and multivariable logistic regression for kidney function decline. Both analyses adjusted for demographics, eGFR, urinary albumin-creatinine ratio, and other kidney disease progression risk factors. RESULTS: Mean age of the random subcohort was 78 years, 40% were men, 15% were black. Mean sUMOD level was 127±64ng/mL and eGFR was 63±19mL/min/1.73m2. In multivariable analysis, each 1-SD higher sUMOD level was associated with 63% lower risk for ESKD (HR, 0.37; 95% CI, 0.14-0.95). In demographic-adjusted analyses of kidney function decline, each 1-SD higher sUMOD level was associated with 25% lower odds of kidney function decline (OR, 0.75; 95% CI, 0.60-0.95); after multivariable adjustment, the association was attenuated and no longer significant (OR, 0.88; 95% CI, 0.68-1.14). LIMITATIONS: Possibility of survival bias in the kidney function decline analysis. CONCLUSIONS: Higher sUMOD levels may identify elderly persons at reduced risk for ESKD.
Authors: Andrew D Rule; Hatem Amer; Lynn D Cornell; Sandra J Taler; Fernando G Cosio; Walter K Kremers; Stephen C Textor; Mark D Stegall Journal: Ann Intern Med Date: 2010-05-04 Impact factor: 25.391
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Sebastian Bachmann; Kerim Mutig; James Bates; Pia Welker; Beate Geist; Volkmar Gross; Friedrich C Luft; Natalia Alenina; Michael Bader; Bernd J Thiele; Krishna Prasadan; Hajamohideen S Raffi; Satish Kumar Journal: Am J Physiol Renal Physiol Date: 2004-11-02
Authors: Tarek M El-Achkar; Ruth McCracken; Yan Liu; Monique R Heitmeier; Soline Bourgeois; Jan Ryerse; Xue-Ru Wu Journal: Am J Physiol Renal Physiol Date: 2013-02-06
Authors: Andreas Leiherer; Axel Muendlein; Christoph H Saely; Eva M Brandtner; Kathrin Geiger; Peter Fraunberger; Heinz Drexel Journal: J Hypertens Date: 2018-01 Impact factor: 4.844
Authors: Danuta Fedak; Marek Kuźniewski; Andrzej Fugiel; Ewa Wieczorek-Surdacka; Bernadetta Przepiórkowska-Hoyer; Piotr Jasik; Przemysław Miarka; Paulina Dumnicka; Maria Kapusta; Bogdan Solnica; Władysław Sułowicz Journal: Pol Arch Med Wewn Date: 2016-12-05
Authors: Pranav S Garimella; Mary L Biggs; Ronit Katz; Joachim H Ix; Michael R Bennett; Prasad Devarajan; Bryan R Kestenbaum; David S Siscovick; Majken K Jensen; Michael G Shlipak; Paulo H M Chaves; Mark J Sarnak Journal: Kidney Int Date: 2015-07-08 Impact factor: 10.612
Authors: Dominik Steubl; Petra Buzkova; Joachim H Ix; Prasad Devarajan; Michael R Bennett; Paolo H M Chaves; Michael G Shlipak; Nisha Bansal; Mark J Sarnak; Pranav S Garimella Journal: Nephrology (Carlton) Date: 2019-12-27 Impact factor: 2.506
Authors: Meng Wang; Zeneng Wang; Stanley L Hazen; Dariush Mozaffarian; Yujin Lee; Heidi T M Lai; Marcia C de Oliveira Otto; Rozenn N Lemaitre; Amanda Fretts; Nona Sotoodehnia; Matthew Budoff; Joseph A DiDonato; Barbara McKnight; W H Wilson Tang; Bruce M Psaty; David S Siscovick Journal: Arterioscler Thromb Vasc Biol Date: 2022-08-01 Impact factor: 10.514
Authors: Joe Chan; My Svensson; Tone M Tannæs; Bard Waldum-Grevbo; Trond Jenssen; Ivar A Eide Journal: Am J Nephrol Date: 2022-02-01 Impact factor: 4.605
Authors: Cornelia Then; Holger L Then; Andreas Lechner; Barbara Thorand; Christa Meisinger; Margit Heier; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Jürgen Scherberich; Jochen Seissler Journal: Clin Kidney J Date: 2020-05-01
Authors: Andrea Galassi; Eliana Maria Fasulo; Paola Ciceri; Roberta Casazza; Fabrizio Bonelli; Claudia Zierold; Mariella Calleri; Frank A Blocki; Maria Assunta Palmieri; Claudio Mastronardo; Mario G Cozzolino Journal: Front Med (Lausanne) Date: 2022-03-02
Authors: Yong Li; Yurong Cheng; Francesco Consolato; Guglielmo Schiano; Michael R Chong; Maik Pietzner; Ngoc Quynh H Nguyen; Nora Scherer; Mary L Biggs; Marcus E Kleber; Stefan Haug; Burulça Göçmen; Marie Pigeyre; Peggy Sekula; Inga Steinbrenner; Pascal Schlosser; Christina B Joseph; Jennifer A Brody; Morgan E Grams; Caroline Hayward; Ulla T Schultheiss; Bernhard K Krämer; Florian Kronenberg; Annette Peters; Jochen Seissler; Dominik Steubl; Cornelia Then; Matthias Wuttke; Winfried März; Kai-Uwe Eckardt; Christian Gieger; Eric Boerwinkle; Bruce M Psaty; Josef Coresh; Peter J Oefner; Guillaume Pare; Claudia Langenberg; Jürgen E Scherberich; Bing Yu; Shreeram Akilesh; Olivier Devuyst; Luca Rampoldi; Anna Köttgen Journal: JCI Insight Date: 2022-05-23
Authors: Stephan Kemmner; Christopher Holzmann-Littig; Helene Sandberger; Quirin Bachmann; Flora Haberfellner; Carlos Torrez; Christoph Schmaderer; Uwe Heemann; Lutz Renders; Volker Assfalg; Tarek M El-Achkar; Pranav S Garimella; Jürgen Scherberich; Dominik Steubl Journal: J Clin Med Date: 2021-06-11 Impact factor: 4.241